ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -5 مورد

Sensitivity of patients with neuromuscular disease to neuromuscular blocking agents

Sensitivity of patients with neuromuscular disease to neuromuscular blocking agents
Disorder type Response to succinylcholine Response to nondepolarizing NMBA
Myasthenic syndromes
  • Myasthenia gravis
Resistant Sensitive
  • Lambert-Eaton myasthenic syndrome
Sensitive Sensitive
  • Congenital myasthenic syndromes
Variable, not recommended due to potential hyperkalemic response Sensitive
Malignant hyperthermia, central core disease, King-Denborough syndrome Contraindicated Normal
Demyelinating diseases
  • Multiple sclerosis
Avoid use Sensitive
  • Motor neuron diseases
Avoid use Sensitive
  • Guillain-Barré syndrome
Avoid use Sensitive
  • Charcot-Marie-Tooth disease (CMTD)
Avoid use Normal
Primary muscle diseases
Muscular dystrophies Contraindicated Sensitive
    • Duchenne muscular dystrophy
Contraindicated Sensitive
    • Becker muscular dystrophy
Contraindicated Sensitive
    • Limb-girdle dystrophy
Contraindicated Sensitive
    • Congenital muscular dystrophy
Contraindicated Sensitive
    • Facioscapulohumeral muscular dystrophy
Contraindicated Sensitive
    • Myotonic dystrophy
Contraindicated Sensitive*
Mitochondrial myopathies Sensitive Sensitive
Motor neuron diseases
Amyotrophic lateral sclerosis (Lou Gehrig's disease) Avoid use Sensitive
Channelopathies
  • Acquired neuromyotonia
Avoid use Normal*
  • Myotonia congenita
Avoid use
  • Paramyotonia congenita
Avoid use
  • Potassium aggravated myotonia
Avoid use
  • Hyperkalemic periodic paralysis
Avoid use
  • Hypokalemic periodic paralysis
Avoid use
Spinal cord injury, stroke, immobility, ICU patients Avoid use Resistant
Metabolic myopathies
Storage disorders (lipid, glycogen) Avoid use Variable – avoid use if possible
NMBA: neuromuscular blocking agent; ICU: intensive care unit.
* Anticholinesterase drugs should be avoided because they may provoke a myotonic reaction.
¶ Carnitine palmitoyltransferase II (CPT II) deficiency; myophosphorylase deficiency (McArdle disease).
Adapted from: Brull SJ. Neuromuscular blocking agents. In: Clinical Anesthesia, 8th ed, Barash PG, Cullen BF, Stoelting RK, et al (Eds), Wolters Kluwer 2017. p.527.
Graphic 114209 Version 3.0